Clinical Trial Update: QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update on QL1706 combined with chemotherapy ± bevacizumab as first-line treatment for metastatic cervical cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Chemotherapy (chemotherapy)
• QL1706

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: METASTATIC CERVICAL CANCER | Phase 3 | Status: UNKNOWN